Another oral small-molecule GLP-1 drug has reached the point of publishing trial data, which matters to a price desk because tablets are manufactured differently from peptides and are not limited by the same capacity constraints [1] — the manufacturing argument set out in what semaglutide costs to make. The one that reached approval is covered on this site’s sister publication.
Over 26 weeks, HbA1c fell between 0.91 and 1.88 percentage points across the elecoglipron doses against 0.15 on placebo, with the largest reduction at 75 mg using a two-weekly escalation schedule. That is a competitive range for a diabetes drug at this stage.
The comparator arm needs its asterisk. Oral semaglutide was included at 14 mg, but open-label, while every elecoglipron dose and its matched placebo were masked. That is a reasonable practical choice and it means the trial cannot be read as a head-to-head against semaglutide, however tempting the arrangement makes it.
The adverse event pattern is the most transferable finding. Rates ran from 63% at the lowest dose — identical to the 63% seen on placebo — up to 87% at the highest dose with the fastest escalation, with the usual nausea, constipation, diarrhea and vomiting. Tolerability tracked dose and escalation speed rather than the drug itself, which is what the titration literature has consistently found and what makes schedule a lever rather than a formality.
Nothing here is purchasable — this is phase 2b, and the authors frame it as supporting continued development into phase 3. What it signals for a buyer is that the oral category is getting crowded, with elecoglipron from one manufacturer, orforglipron approved from another, and oral semaglutide already on sale. More competitors in a format that scales better is the condition under which prices usually move, which is the question examined in what semaglutide costs to make and what a GLP-1 actually costs.